Advancing mRNA-based drug development and vaccine manufacturing
Shared by Parexel experts, Christiane Niederlaender, Cecil Nick, and Sinan Sarac covering on the topics of:
Section 1 - Overview of mRNA Product Manufacturing Challenges
Section 2 - Optimizing the Path to Regulatory Approval for Novel Vaccine
Section 3 - Accelerating Approval of mRNA vaccines for Oncology Drug development
Related Insights
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Article
New endpoints for early-stage cancer are gaining regulatory traction
Jan 28, 2022
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Webinar
How to navigate China’s regulatory environment
Feb 15, 2023
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022
Playbook
Are you using real-world evidence?
Feb 1, 2023
Related Insights
Webinar
Navigating the complexities of AML drug development
Oct 30, 2024
Blog
Making cell and gene therapy more accessible in the treatment of solid tumors
Jun 4, 2024
Webinar
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Nov 12, 2024
Article
Q&A Project Optimus: What you need to know
Oct 11, 2022
Article
New endpoints for early-stage cancer are gaining regulatory traction
Jan 28, 2022
Blog
PD-1 inhibitors face scrutiny in esophageal cancer: Key takeaways for drug developers
Oct 4, 2024
Article
Five strategies for meeting the requirements of Project Optimus and improving the chances of approval
Nov 10, 2022
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Webinar
How to navigate China’s regulatory environment
Feb 15, 2023
Article
Relyvrio Approval: Lessons Learned
Oct 31, 2022
Playbook
Are you using real-world evidence?
Feb 1, 2023